Robert A. Bradway - 27 Apr 2022 Form 4 Insider Report for AMGEN INC (AMGN)

Role: Chairman, CEO and President, Director
Signature: /s/ Robert A. Bradway
Issuer symbol: AMGN
Transactions as of: 27 Apr 2022
Transactions value $: -$636,419
Form type: 4
Filing time: 29 Apr 2022, 18:37:52 UTC
Previous filing: 05 Apr 2022
Next filing: 04 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMGN	Common Stock	Tax liability	-$636K	-2.55K	-0.42%	$249.87	611K	27 Apr 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares include the following RSUs granted under the Company's equity plans: 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F2	These shares include 2,174 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Content

These shares include the following RSUs granted under the Company's equity plans: 10,580 RSUs which vest in installments of 5,211 on 5/3/2022 and 5,369 on 5/3/2023; 12,184 RSUs which vest in installments of 4,020 on 5/05/2022, 4,021 on 5/5/2023 and 4,143 on 5/5/2024; and 13,280 RSUs which vest in two installments of 4,382 on 4/30/2023 and 4/30/2024 and one installment of 4,516 on 4/30/2025. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.

These shares include 2,174 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.